Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Domenico De Fazio is active.

Publication


Featured researches published by Domenico De Fazio.


Clinical Infectious Diseases | 2005

Facial Lipohypertrophy in HIV-Infected Subjects Who Underwent Autologous Fat Tissue Transplantation

Giovanni Guaraldi; Domenico De Fazio; Gabriella Orlando; Rita Murri; Albert W. Wu; Pietro Guaraldi; Roberto Esposito

Of 41 HIV-infected patients with facial lipoatrophy who underwent autologous fat transplantation, disfiguring facial lipohypertrophy at the graft site occurred at the same time as recurrent fat accumulation at the tissue harvest site in 4 patients who had had fat transferred from the dorsocervical fat pad or from subcutaneous abdominal tissue.


Hiv Clinical Trials | 2006

Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy

Giovanni Guaraldi; Gabriella Orlando; Nicola Squillace; Giorgio De Santis; Antonio Pedone; A. Spaggiari; Domenico De Fazio; M. Vandelli; Maria De Paola; Costantino Bertucelli; Cristina Aldrovandi; Giulia Nardini; Barbara Beghetto; Vanni Borghi; Marco Bertolotti; Bruno Bagni; Maria Grazia Amorico; Alberto Roverato; Roberto Esposito

Abstract Background: Treatment for metabolic and morphologic alterations in HIV-related lipodystrophy include medical therapy, physical exercise, and surgical interventions. Method: We assessed the efficacy and safety of a comprehensive multidisciplinary approach for treating morphological and metabolic alterations of the lipodystrophy syndrome in consecutive patients attending the Metabolic Clinic (MC) of the University of Modena and Reggio Emilia who had at least 2 evaluations over a 48-week period. 245 patients were evaluated: 143 (62.4%) were men, 74 (36.1%) presented with lipoatrophy, 10 (4.9%) with fat accumulation, 93 (45%) with mixed forms, 24 (11.3%) had hypercholesterolemia (LDL >160 mg/dL), 87 (38%) had hypertriglyceridemia (TG >150 mg/dL), 13 (5.7%) had diabetes (glucose >126 mg/dL), and 78 (44%) had insulin resistance (HOMA-IR >4). Results: At follow-up, a significant improvement was observed in both objective and subjective variables. Anthropometric improvement was observed in waist to hip ratio, waist circumference, and right and left cheek dermal thickness measurements. A nonsignificant improvement was observed in fat and lean regional mass by DEXA; CT showed improvement in visceral and subcutaneous adipose tissue. Glucose, HOMA-IR, total cholesterol, and APO B improved. Subjective variables improved in aesthetic satisfaction. Conclusion: We conclude that the medical and surgical interventions proposed in this multidisciplinary therapeutic approach are efficacious and safe in the management of lipodystrophy.


AIDS | 2011

Surgical correction of HIV-associated facial lipoatrophy.

Giovanni Guaraldi; Joan Fontdevila; Lise Christensen; Gabriella Orlando; Chiara Stentarelli; Federica Carli; Stefano Zona; Giorgio De Santis; Antonio Pedone; Domenico De Fazio; Pierluigi Bonucci; Esteban Martínez

Lipodystrophy was first described in HIV-1-infected patients in 1998 [1–5]. The main clinical feature is subcutaneous fat loss or lipoatrophy of the face, limbs, and buttocks [6,7]. Patients can also experience fat accumulation within the abdomen, neck or breasts [8,9]. The pathogenesis of lipoatrophy appears to be multifactorial. Contributing factors are CD4þ lymphocyte cell count, HIV clinical stage, race, sex, exercise level, age at start of antiretroviral therapy [8], and the rapidity of its onset may depend on the individual total fat mass. The driving force behind lipoatrophy is undoubtedly the cumulative exposure to thymidine analogue drugs. These drugs, in particular stavudine and to a lesser extent zidovudine, block mitochondrial DNA polymerase function producing apoptosis of fat cells [9,10]. Earlier detection and treatment of HIV infection [11], as well as the use of antiretroviral drugs with less deleterious effects on body fat, make it reasonable to hypothesize a decrease in prevalence of lipodystrophy in the coming years.


Journal of Acquired Immune Deficiency Syndromes | 2007

Prevalence of and risk factors for pubic lipoma development in HIV-infected persons.

Giovanni Guaraldi; Gabriella Orlando; Nicola Squillace; Alberto Roverato; Domenico De Fazio; M. Vandelli; Giulia Nardini; Barbara Beghetto; Maria De Paola; Roberto Esposito; Frank J. Palella

Background:The natural history of HIV-associated body habitus changes is unclear. In this report, we describe a novel manifestation of HIV-associated lipoaccumulation. Methods:We noted the presence of suprapubic fat pads (pubic lipomas [PLs]) in several patients with preexisting HIV-associated body habitus abnormalities. Subsequently, we evaluated the prevalence of and associated risk factors for development of PLs by undertaking an observational cross-sectional study among patients with known lipodystrophy who attended a metabolic clinic in northern Italy. Inclusion criteria were a physician-confirmed diagnosis of lipodystrophy according to the Multicenter AIDS Cohort Study definition and, for those affected with PL, a readily noticeable PL on physical examination. Results:We evaluated 582 patients with lipodystrophy: 214 female (36.7%) and 368 male (63.3%). The overall PL prevalence was 9.4% (95% confidence interval [CI]: 7.2% to 12.1%; P < 0.0001). PLs were more common among obese than nonobese individuals (34.5%, 95% CI: 17.9% to 5l.3% vs. 8%, 95% CI: 5.9% to 10.6%, respectively; P < 0.0001) and those with preexisting dorsocervical fat pads, commonly called “buffalo humps” (BHs) (18.5%, 95% CI: 12.7% to 25.4% vs. 6.1%, 95% CI: 4.03% to 8.83%, respectively, P < 0.0001; relative risk = 3.02, 95% CI: 1.84% to 4.96%, P < 0.0001). The PL prevalence in the nonobese HIV-infected population (body mass index [BMI] <30, n = 550) was 8.0% (95% CI: 5.9% to 10.6%; P < 0.0001). Logistic regression analyses identified the following factors as associated with a greater likelihood for PL: BMI >30 (β = 0.18, SE = 0.04; P < 0.001), female gender (β = 1.06, SE = 0.31; P < 0.001), and shorter duration of HIV infection (β = −0.005, SE = 0.003; P = 0.04). We used a chain graph model to evaluate risk factors for BH and PL simultaneously. A nonnull interaction between these entities was evident, and this association seemed to be independent of factors positively associated with both (BMI and gender). Conclusions:PL is a newly recognized manifestation of HIV-associated lipoaccumulation that is more likely to occur among those with coexisting dorsocervical fat pads, suggesting the possibility of a common pathogenesis between the 2 entities. Likewise, PLs are more common among women, obese individuals, and those with a shorter duration of HIV infection. We suggest that PL should be considered part of the HIV-associated lipodystrophy syndrome.


Archive | 2012

Comparison of Three Different Methods for Correction of HIV-Associated Facial Lipodystrophy

Giovanni Guaraldi; Pier Luigi Bonucci; Domenico De Fazio

HIV-1-infected patients can have peripheral fat loss or lipoatrophy of the face, limbs, and buttocks and central fat accumulation within the abdomen, breast, and the dorso-cervical spine both of which may be present in the same individual. Lipoatrophy causes negative psychosocial impact and an impairment of quality of life because of erosion of self-image and self-esteem, demoralization and depression, problems in social and sexual relations, and threats to locus of control.


Antiviral Therapy | 2005

Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy : a prospective study

Giovanni Guaraldi; Gabriella Orlando; Domenico De Fazio; Ilario De Lorenzi; Antonio Rottino; Giorgio De Santis; Antonio Pedone; A. Spaggiari; Alessio Baccarani; Vanni Borghi; Roberto Esposito


Aids Patient Care and Stds | 2007

Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study.

Gabriella Orlando; Giovanni Guaraldi; Domenico De Fazio; A. Rottino; A. Grisotti; M. Blini; G. De Santis; Antonio Pedone; A. Spaggiari; Alessio Baccarani; M. Vandelli; M. De Paola; D. Comelli; Giulia Nardini; Barbara Beghetto; Nicola Squillace; Roberto Esposito


Antiviral Therapy | 2005

Autologous fat transfer for the treatment of HIV-related face lipoatrophy: 1-year follow-up

Giovanni Guaraldi; Gabriella Orlando; Domenico De Fazio; A. Rottino; A. Grisotti; M. Blini; Vanni Borghi; Giulia Nardini; Roberto Esposito


Annals of Internal Medicine | 2009

Heterologous fat transplantation for the treatment of HIV-related facial lipoatrophy

Giovanni Guaraldi; Nicola Squillace; Domenico De Fazio; Tullio Prestileo; Frank J. Palella


Blood | 2007

0.1 Grams of Sub-Cutaneous Adipose Tissue (SCAT) as Source of Adult Multipotent Mesenchymal Stromal Cells (MSC) for Cell-Based Therapies.

Massimo Dominici; Rita Sternieri; Domenico De Fazio; Luigi Cafarelli; Giovanni Guaraldi; Carlotta Spano; Valeria Rasini; Paolo Paolucci; Michele Cilli; Federica Piccardi; Giuseppe Astori; Ted J. Hofmann; Edwin M. Horwitz; Pierfranco Conte

Collaboration


Dive into the Domenico De Fazio's collaboration.

Top Co-Authors

Avatar

Giovanni Guaraldi

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Gabriella Orlando

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Roberto Esposito

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Giulia Nardini

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Barbara Beghetto

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Nicola Squillace

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Antonio Pedone

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

M. Vandelli

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar

Vanni Borghi

University of Modena and Reggio Emilia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge